Over the long term, Levin expects oral GLP-1s to gain favor over injectables. Most patients prefer pills to injections, and ...

Two large real-world analyses presented at ACTRIMS Forum 2026 shed new light on the multiple sclerosis (MS) care continuum, ...

Ultimately, effective treatment selection integrates rigorous evaluation of evidence with individualized discussions of safety, efficacy, convenience, and patient values. By tailoring therapy to ...

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.

Incremental dose to neurogenic niches correlated with reduced overall survival: SVZ HR 1.306/Gy and hippocampus HR 1.222/Gy, indicating independent adverse prognostic impact.

As the HIV research community prepares to convene for the Conference on Retroviruses and Opportunistic Infections (CROI) 2026 ...

This episode, titled Positioning Emerging Targeted Therapies in the Evolving IgA Nephropathy Treatment Paradigm, features ...

In the final episode, Assessing Long-Term Renal Outcomes and Kidney Failure Risk Reduction in IgA Nephropathy, the panelists ...

A US-focused cohort study published in 2023 showed similar trends, with a higher AA incidence observed among women (range, ...

From clinic closures to gene therapy costs, new data reveal how policy, prices, and structural racism reshape US health ...

City leaders share real-world GLP-1 coverage tactics, showing how public employers balance access, costs, and lasting ...

Emerging HER2-targeted therapies in lung cancer highlight the importance of real-world data and survival metrics for patient ...